Gene control life sciences company Syros Pharmaceuticals has raised its first ever round of funding with a $30m series A round from Flagship Ventures, Arch Venture Partners and WuXi PharmTech Corporate Venture Fund.

WuXi PharmaTech Corporate Venture, part of the eponymous China-based drugs maker, has participated in a $30 series A round of funding into US-based biotech start-up Syros Pharmaceuticals. Syros has also picked Nancy Simonian, formally of Millennium Pharmaceuticals, as chief executive. Venture capital firms Flagship Ventures and Arch Venture Partners led the round with participation from…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.